What is the recommended course of action for patients with NSTE-ACS regarding anticoagulant and antiplatelet therapy?
Class I: All patients with NSTE-ACS should be evaluated for the risk of bleeding. Anticoagulant and antiplatelet therapy should be weight-based where appropriate and should be adjusted when necessary for CKD to decrease the risk of bleeding in patients with NSTE-ACS. (Level of Evidence: B)